

KIDNEY STAGING FORM

CLINICAL <i>Extent of disease before any treatment</i>	STAGE CATEGORY DEFINITIONS	PATHOLOGIC <i>Extent of disease through completion of definitive surgery</i>																																																																							
<input type="checkbox"/> y clinical – staging completed after neoadjuvant therapy but before subsequent surgery	TUMOR SIZE: _____ LATERALITY: <input type="checkbox"/> left <input type="checkbox"/> right <input type="checkbox"/> bilateral	<input type="checkbox"/> y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery																																																																							
<input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> T1 <input type="checkbox"/> T1a <input type="checkbox"/> T1b <input type="checkbox"/> T2 <input type="checkbox"/> T2a <input type="checkbox"/> T2b <input type="checkbox"/> T3 <input type="checkbox"/> T3a <input type="checkbox"/> T3b <input type="checkbox"/> T3c <input type="checkbox"/> T4	PRIMARY TUMOR (T) Primary tumor cannot be assessed No evidence of primary tumor Tumor 7 cm or less in greatest dimension, limited to the kidney Tumor 4 cm or less in greatest dimension, limited to the kidney Tumor more than 4 cm but not more than 7 cm in greatest dimension limited to the kidney Tumor more than 7 cm in greatest dimension, limited to the kidney Tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney Tumor more than 10 cm, limited to the kidney Tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota's fascia Tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota's fascia Tumor grossly extends into the vena cava below the diaphragm Tumor grossly extends into the vena cava above the diaphragm or invades the wall of the vena cava Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)	<input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> T1 <input type="checkbox"/> T1a <input type="checkbox"/> T1b <input type="checkbox"/> T2 <input type="checkbox"/> T2a <input type="checkbox"/> T2b <input type="checkbox"/> T3 <input type="checkbox"/> T3a <input type="checkbox"/> T3b <input type="checkbox"/> T3c <input type="checkbox"/> T4																																																																							
<input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1	REGIONAL LYMPH NODES (N) Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis	<input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1																																																																							
<input type="checkbox"/> M0 <input type="checkbox"/> M1	DISTANT METASTASIS (M) No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis	<input type="checkbox"/> M1																																																																							
ANATOMIC STAGE • PROGNOSTIC GROUPS																																																																									
<table border="0" style="width: 100%;"> <thead> <tr> <th style="width: 10%;"></th> <th colspan="3" style="text-align: center;">CLINICAL</th> </tr> <tr> <th>GROUP</th> <th>T</th> <th>N</th> <th>M</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td><input type="checkbox"/> II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td><input type="checkbox"/> III</td> <td>T1 or T2</td> <td>N1</td> <td>M0</td> </tr> <tr> <td></td> <td>T3</td> <td>N0 or N1</td> <td>M0</td> </tr> <tr> <td><input type="checkbox"/> IV</td> <td>T4</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td></td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> <tr> <td colspan="4"><input type="checkbox"/> Stage unknown</td> </tr> </tbody> </table>		CLINICAL			GROUP	T	N	M	<input type="checkbox"/> I	T1	N0	M0	<input type="checkbox"/> II	T2	N0	M0	<input type="checkbox"/> III	T1 or T2	N1	M0		T3	N0 or N1	M0	<input type="checkbox"/> IV	T4	Any N	M0		Any T	Any N	M1	<input type="checkbox"/> Stage unknown				<table border="0" style="width: 100%;"> <thead> <tr> <th style="width: 10%;"></th> <th colspan="3" style="text-align: center;">PATHOLOGIC</th> </tr> <tr> <th>GROUP</th> <th>T</th> <th>N</th> <th>M</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td><input type="checkbox"/> II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td><input type="checkbox"/> III</td> <td>T1 or T2</td> <td>N1</td> <td>M0</td> </tr> <tr> <td></td> <td>T3</td> <td>N0 or N1</td> <td>M0</td> </tr> <tr> <td><input type="checkbox"/> IV</td> <td>T4</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td></td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> <tr> <td colspan="4"><input type="checkbox"/> Stage unknown</td> </tr> </tbody> </table>		PATHOLOGIC			GROUP	T	N	M	<input type="checkbox"/> I	T1	N0	M0	<input type="checkbox"/> II	T2	N0	M0	<input type="checkbox"/> III	T1 or T2	N1	M0		T3	N0 or N1	M0	<input type="checkbox"/> IV	T4	Any N	M0		Any T	Any N	M1	<input type="checkbox"/> Stage unknown			
	CLINICAL																																																																								
GROUP	T	N	M																																																																						
<input type="checkbox"/> I	T1	N0	M0																																																																						
<input type="checkbox"/> II	T2	N0	M0																																																																						
<input type="checkbox"/> III	T1 or T2	N1	M0																																																																						
	T3	N0 or N1	M0																																																																						
<input type="checkbox"/> IV	T4	Any N	M0																																																																						
	Any T	Any N	M1																																																																						
<input type="checkbox"/> Stage unknown																																																																									
	PATHOLOGIC																																																																								
GROUP	T	N	M																																																																						
<input type="checkbox"/> I	T1	N0	M0																																																																						
<input type="checkbox"/> II	T2	N0	M0																																																																						
<input type="checkbox"/> III	T1 or T2	N1	M0																																																																						
	T3	N0 or N1	M0																																																																						
<input type="checkbox"/> IV	T4	Any N	M0																																																																						
	Any T	Any N	M1																																																																						
<input type="checkbox"/> Stage unknown																																																																									

HOSPITAL NAME/ADDRESS	PATIENT NAME/INFORMATION
------------------------------	---------------------------------

(continued on next page)

KIDNEY STAGING FORM

PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)

REQUIRED FOR STAGING: None

CLINICALLY SIGNIFICANT:

Invasion beyond capsule into fat or perisinus tissues: _____

Venous involvement: _____

Adrenal Extension: _____

Fuhrman Grade: _____

Sarcomatoid features: _____

Histologic tumor necrosis: _____

Extranodal extension: _____

Size of metastasis in lymph nodes: _____

Histologic Grade (G) (also known as overall grade)

Grading system

- 2 grade system
- 3 grade system
- 4 grade system
- No 2, 3, or 4 grade system is available

Grade

- Grade I or 1
- Grade II or 2
- Grade III or 3
- Grade IV or 4

ADDITIONAL DESCRIPTORS

Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

Residual Tumor (R)

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

General Notes:

For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.

r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.

a prefix designates the stage determined at autopsy: aTNM.

surgical margins is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

Clinical stage was used in treatment planning (describe): _____

National guidelines were used in treatment planning NCCN Other (describe): _____

Physician signature

Date/Time


<p>HOSPITAL NAME/ADDRESS</p> 	<p>PATIENT NAME/INFORMATION</p>
---	--

(continued from previous page)

KIDNEY STAGING FORM

Illustration

Indicate on diagram primary tumor and regional nodes involved.



HOSPITAL NAME/ADDRESS

PATIENT NAME/INFORMATION